How well does Vocabria(Cabotegravir) work?

Clinical trials demonstrate efficacy in maintaining viral suppression for treatment and reducing HIV-1 acquisition for PrEP.

Therapeutic Effects

In HIV-1 treatment trials (e.g., FLAIR, ATLAS), VOCABRIA with EDURANT showed non-inferiority in maintaining virologic suppression (HIV-1 RNA <50 copies/mL) compared to standard regimens over 48-124 weeks. For PrEP, studies like HPTN 083 and 084 confirmed significant reduction in HIV-1 infection risk among high-risk populations when used as directed. Efficacy is supported in adolescents and adults, with proper adherence ensuring optimal outcomes in both indications.